Fagron Stock

Fagron Equity

The The Equity of Fagron (FAGR.BR) as of Aug 17, 2026 is 551.61 M EUR. In the previous year, The Equity was 501.39 M EUR — a change of 10.02% (higher).

Equity

551.61 MEUR

YoY

10.02%

Last updated:

In 2026, Fagron's equity was 551.61 M EUR, a 10.02% increase from the 501.39 M EUR equity in the previous year.

Access this data via the Eulerpool API

Fagron Stock analysis

What does Fagron do? Fagron NV is an internationally operating company that focuses on the development and production of customized medications for pharmacies and hospitals. The company was founded in 1990 in Rotterdam, Netherlands. The beginnings of Fagron NV were in the Netherlands, where the company was established as Roterodamum Chemie BV. In the late 1990s, the company was converted into a holding company called Arseus NV, which later received the name Fagron. In 2012, Fagron was listed on the Euronext stock exchange in Brussels. Fagron operates globally and has locations in Europe, North America, Latin America, the United Arab Emirates, Asia, and Australia. Fagron's business model is based on the production of specialized medications for individual patient needs. The company offers a wide range of pharmaceutical active ingredients, raw materials, and processing services. There is also the possibility to develop and manufacture customized formulations tailored to the needs of patients. Fagron not only manufactures customized medications but also provides training and support for pharmacies and hospitals. Fagron operates in three main divisions: Specialty Pharma (hospital care), Community Pharma (prescription and non-prescription medications), and Compounding Services (custom formulations). The Specialty Pharma division specializes in medications for use in hospitals. It offers a wide range of products that can be used in the treatment of conditions such as cancer, HIV, and tuberculosis. These medications are manufactured in various dosage forms, such as injections, infusions, and tablets. The Community Pharma division focuses on prescription and non-prescription medications. Both branded and generic medications are offered. These are delivered directly to pharmacies, hospitals, and clinics. The Compounding Services division specializes in the production of customized medications. Fagron works closely with pharmacies and hospitals to meet individual needs. This includes, for example, the manufacture of medications in specific dosages or the combination of several active ingredients in a custom formulation. Fagron offers a wide range of products, including hormones, pain medications, cancer drugs, medications for the treatment of skin diseases, ophthalmic products, and anti-infectives. Pharmaceutical active ingredients and raw materials are also offered. Overall, Fagron is a global leader in the production of customized medications. It has extensive experience and expertise in the manufacturing of pharmaceutical formulations and offers a wide range of products and services. The various divisions of Fagron allow the company to meet the diverse needs of its customers and maintain its position as a leading company in the pharmaceutical industry. Fagron is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Fagron's Equity

Fagron's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Fagron's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Fagron's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Fagron's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Fagron’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Fagron stock

The Equity of Fagron is 551.61 M EUR in 2026.

The Equity of Fagron changed from 501.39 M EUR to 551.61 M EUR, representing a 10.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Fagron since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Fagron historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Fagron

All Key Metrics — Fagron